Immunisation & Treatment - New approaches to influenza prevention and treatment - lessons learnt from COVID- 19

Nationality: British 

Position: Respiratory physician and mucosal immunologist, Professor of Experimental Medicine, Imperial College, London

Research fields: Lung immunology, RSV, received a lifetime achievement in work on RSV research (Chanock prize, US, in 2012)

ESWI member since 2008

Peter Openshaw is a respiratory physician and mucosal immunologist, studying how the immune system both protects against viral infection but also causes disease. He has worked on RSV and influenza since the mid-1980s, leading a large Wellcome Trust funded national collaboration: Mechanisms of Severe Acute Influenza Consortium MOSAIC (2009-12), recruiting cases of severe influenza during the influenza pandemic of 2009-2010.

He has run studies of human experimental infection of volunteers for over 12 years and is Director of the MRC-funded HIC-Vac consortium established to promote the use of human experimental infection to accelerate vaccine development for pathogens of high global impact. Furthermore, he served as President of the British Society for Immunology (2013-18) and is a member of the Academy of Medical Sciences–British Society for Immunology expert taskforce on the immunology of COVID-19.

He has been a member of SAGE (2009-12), Chair and now vice-Chair or NERVTAG, a Department of Health committee horizon-scanning for emerging respiratory threats. He is a member of the UK Vaccine Network and several committees and Boards that oversee research on the immunology of respiratory infection.

He is Theme Lead for Infection at the Imperial Biomedical Research Centre, Respiratory Infections Section Head within the National Heart and Lung Institute and an NIHR Senior Investigator. He co-leads ISARIC4C, a UK-wide consortium established in 2020 to study the COVID-19 pandemic.

Prof Anthony Gordon is the Chair in Anaesthesia and Critical Care at Imperial College London, an NIHR Senior Investigator, and works as an Intensive Care consultant at St Mary’s Hospital. His research focuses on developing precision medicine in sepsis.

He leads a multidisciplinary group investigating the use of -omic techniques and artificial intelligence (AI) to improve outcomes in sepsis, with a particular focus on clinical trials and translational studies. He is the UK Chief Investigator for the international REMAP-CAP trial for COVID-19 and influenza, that has generated evidence that has improved treatments for severe COVID-19 around the world.

https://www.imperial.ac.uk/people/anthony.gordon

Nationality: German



Position: Professor of Pulmonary Infections Universities Giessen & Marburg Lung Center, and Head of the Infectious Diseases Department at the Giessen University Hospital, Giessen, Germany



Research fields: Influenza Viruses , pneumonia and coronaviruses



ESWI member from 2016 – 2022



Associate member since 2022



Professor Susanne Herold studied medicine at the University of Giessen from 1995 to 2002. She received her doctorate in 2003 with a thesis on monocytes in the lungs and acquired her PhD 2008 at the University of Giessen. Since 2013, she has been a visiting professor at Northwestern University in Chicago for the Department of Pulmonary and Intensive Care Medicine.



In 2018, Susanne Herold took over the professorship for infectious diseases of the lungs at the University of Giessen and at the same time became head of the Infectious Diseases Department at the Giessen University Hospital.



She has been a member of numerous specialist societies, including the Academy of Charitable Sciences in Erfurt and the German Center for Infection Research since 2017. She is also a member of the Scientific Advisory Board of the Robert Koch Institute and deputy chairman of the German Society for Infectious Diseases. Since 2016, Prof. Herold has been leading a DFG- funded clinical research project on lung damage caused by viruses.